What is Zacks Research’s Forecast for BAX FY2025 Earnings?

Baxter International Inc. (NYSE:BAX) – Investment analysts at Zacks Research decreased their FY2025 earnings per share estimates for shares of Baxter International in a research note issued to investors on Thursday, November 20th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $2.36 per share for the year, down from their prior estimate of $2.45. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q1 2026 earnings at $0.47 EPS, Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.60 EPS, Q4 2026 earnings at $0.55 EPS, Q1 2027 earnings at $0.52 EPS, Q2 2027 earnings at $0.64 EPS and Q3 2027 earnings at $0.70 EPS.

Several other research firms also recently issued reports on BAX. Citigroup dropped their target price on Baxter International from $26.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Wall Street Zen downgraded Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Jefferies Financial Group reduced their target price on shares of Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baxter International in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. cut their price objective on Baxter International from $25.00 to $19.00 in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $23.70.

Baxter International Stock Up 5.1%

Baxter International stock opened at $18.30 on Friday. Baxter International has a fifty-two week low of $17.40 and a fifty-two week high of $37.74. The firm’s 50-day simple moving average is $21.28 and its 200 day simple moving average is $25.65. The stock has a market cap of $9.41 billion, a PE ratio of -61.00, a price-to-earnings-growth ratio of 0.73 and a beta of 0.57. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, beating the consensus estimate of $0.60 by $0.09. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.88 billion. During the same period in the prior year, the business posted $0.80 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS.

Hedge Funds Weigh In On Baxter International

A number of hedge funds have recently made changes to their positions in BAX. Zions Bancorporation National Association UT bought a new stake in Baxter International in the first quarter worth $27,000. CoreFirst Bank & Trust bought a new position in Baxter International during the 2nd quarter worth about $27,000. Imprint Wealth LLC bought a new position in Baxter International in the third quarter worth approximately $27,000. Creative Financial Designs Inc. ADV boosted its holdings in shares of Baxter International by 169.6% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 619 shares in the last quarter. Finally, MTM Investment Management LLC acquired a new position in Baxter International during the 2nd quarter valued at about $30,000. Institutional investors own 90.19% of the company’s stock.

Baxter International Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, November 28th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, November 28th. Baxter International’s dividend payout ratio is currently -6.06%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.